公开(公告)号：US20210038740A1

公开(公告)日：2021-02-11

申请号：US17075738

申请日：2020-10-21

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Valery KRIZHANOVSKY ,  Yossi OVADYA

IPC: A61K47/68 ,  A61P35/00 ,  A61K45/06 ,  C07K16/18 ,  C12N15/113

Abstract: A method of targeting a pharmaceutical agent to a senescent cell is disclosed. The method comprises administering the pharmaceutical agent to the subject, wherein said pharmaceutical agent is attached to an affinity moiety, said affinity moiety being capable of binding specifically to a polypeptide selected from the group consisting of HSP90B1, DNAJB4, PI4K2A, DBN1, PRKCSH, SPTBN1, NPM1, ITGA3 and a polypeptide set forth in Table 1. The targeting may be for therapeutics or diagnostics.

公开(公告)号：US20230094083A1

公开(公告)日：2023-03-30

申请号：US18062601

申请日：2022-12-07

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Valery KRIZHANOVSKY ,  Yossi OVADYA

IPC: C07K16/44 ,  A61P43/00

Abstract: Described herein are anti-human Grp94 antibodies. The antibodies may be used to target senescent cells. Thus, the anti-Grp94 antibodies would be useful in treating diseases and conditions associated with cellular senescence. The anti-Grp94 antibodies could target senescent cells in vivo. Therefore, the anti-Grp94 antibodies could be used to target senescent cells associated with age-related diseases in vivo.

公开(公告)号：US20180117173A1

公开(公告)日：2018-05-03

申请号：US15573550

申请日：2016-05-19

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Valery KRIZHANOVSKY ,  Yossi OVADYA

IPC: A61K47/68 ,  C12N15/113 ,  C07K16/18 ,  A61P35/00 ,  A61K45/06

CPC classification number: A61K47/6843 ,  A61K45/06 ,  A61K47/6807 ,  A61K47/6849 ,  A61P35/00 ,  C07K16/18 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2310/3513

Abstract: A method of targeting a pharmaceutical agent to a senescent cell is disclosed. The method comprises administering the pharmaceutical agent to the subject, wherein said pharmaceutical agent is attached to an affinity moiety, said affinity moiety being capable of binding specifically to a polypeptide selected from the group consisting of HSP90B1, DNAJB4, PI4K2A, DBN1, PRKCSH, SPTBN1, NPM1, ITGA3 and a polypeptide set forth in Table 1. The targeting may be for therapeutics or diagnostics.